Arabio & BioFarma Sign MoU to “Establish Arabio as the Manufacturing Hub for BioFarma Vaccines in the MENA Region”
Bandung, Indonesia – 25th February 2025
Arabio, a leading biopharmaceutical company in Saudi Arabia, and BioFarma, a global leader in vaccine development, have signed a Memorandum of Understanding (MOU) under the patronage of the Minister of Health of Saudi Arabia. This strategic agreement aims to establish Arabio as the regional manufacturing hub for vaccines in the MENA region, reinforcing Saudi Arabia’s commitment to localizing vaccine production and enhancing regional healthcare resilience.
Under the MOU, Arabio and BioFarma will collaborate to transfer vaccine manufacturing technology against the backdrop of Saudi Arabia’s localization strategy enabling local production of vaccines and export Saudi-made vaccines across MENA region.
This partnership represents a significant milestone in regional vaccine manufacturing, ensuring long-term sustainability, accessibility, and healthcare resilience across MENA and a significant step toward strengthening local biopharmaceutical capabilities, supporting Vision 2030’s goals of self-sufficiency, and positioning Saudi Arabia as a leader in vaccine manufacturing and supply chain excellence.
Shadiq Akasya
President Director BioFarma Indonesia, said:
"Arabio will be the main manufacturing and distribution center for BioFarma's vaccine in the MENA region, ensuring wider vaccine availability in the region. This is a shared commitment to improve global health security."
The MOU reflects BioFarma’s strategic mission to enhance national healthcare resilience and drive growth in the biopharmaceutical sector through technology transfer, workforce development, and contributions to Saudi Arabia’s Vision 2030.
Abdulrahman Almutairi
Arabio CEO
“Arabio and BioFarma have an important role in ensuring access to high-quality vaccines for countries in the MENA region. This collaboration will strengthen regional manufacturing capacity and support innovation in the field of life sciences. The signing of this MoU is an important achievement not only for Arabio but for the entire health ecosystem at the regional level in the Middle East. We are ready to work with our brothers at BioFarma, to face the journey ahead in building a healthier future in the Middle East Region”
About BioFarma
PT BioFarma (Persero) is the largest pharmaceutical holding company in Indonesia, which offer end-to-end services in the health industry, starting from the pharmaceutical-related research and development, manufacturing, distribution to the operation of pharmacy, health clinics to clinical laboratories. BioFarma’s headquarter is sitting on a 91,058 square meters of land in Bandung, West Java, which comprises office buildings and factory facilities. The company also operates a representative office in Jakarta. With manufacturing capability than is more than 3.2 billion doses of vaccines per year, the company has exported its vaccine products to more than 150 countries in the world. BioFarma is the holding company of two pharmaceutical issuers on the Indonesia Stock Exchange (IDX), namely PT Kimia Farma Tbk (KAEF), PT Indofarma Tbk (INAF). For further information, please visit www.biofarma.co.id
About Arabio
Arab Pharmaceutical Company (“Arabio”) is one of the first biopharmaceutical companies in the region, specialized in human vaccines, and other biopharmaceutical cold chain products. It was established in 2005 and is headquartered in Riyadh, with a manufacturing facility in the heart of Makkah and sales offices in multiple cities across the region. Arabio has formed partnerships with global and regional biopharmaceutical companies, with an aim to provide equitable access to vaccines for citizens and residents of Saudi Arabia, Middle East and North Africa and is for many years the market leader by supplying 10 vaccines which are part of the mandatory vaccination schedule in the Kingdom. Arabio is almost fully owned by Saudi shareholders, namely Khaled Juffali company and Tamer Group as majority shareholder.